Related Experiment Videos
The use of phage display for the development of tumour targeting agents
1Institut für Pharmazeutische Wissenschaften, Eidgenössische Technische Hochschule, CH-8057, Zürich, Switzerland.
Abstract:
One way to improve the selectivity of therapeutic molecules in clinical oncology would be to target them on the tumour site, thereby sparing normal tissues. The development of targeted therapeutic methodologies relies in most cases on the availability of binding molecules specific for tumour-associated markers. The display of repertoires of polypeptides on the surface of filamentous phage, together with the efficient selection-amplification of the desired binding specificities using affinity capture, represents an efficient route towards the isolation of specific peptides and proteins that could act as vehicles for tumour targeting applications. Most investigations in this area of research have so far been performed with phage derived recombinant antibodies, which have been shown to selectively target tumour-associated markers both in preclinical animal models and in the clinic. However, future developments with other classes of polypeptides (small constrained peptides, small globular proteins) promise to be important for the selective delivery of therapeutic agents to the tumour site.
Insights
Phage display technology enables the isolation of specific binding molecules for targeted cancer therapy. This approach facilitates the development of novel therapeutic delivery systems to improve treatment selectivity and spare healthy tissues.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Improving therapeutic molecule selectivity in oncology is crucial for minimizing side effects.
- Targeted delivery relies on identifying binding molecules specific to tumor-associated markers.
- Phage display offers a method for discovering such specific binding molecules.
Purpose of the Study:
- To explore the potential of phage display technology for isolating tumor-targeting molecules.
- To review the application of phage-derived recombinant antibodies in preclinical and clinical settings.
- To highlight future prospects of other polypeptide classes for targeted drug delivery.
Main Methods:
- Utilizing phage display to present repertoires of polypeptides on filamentous phage surfaces.
- Employing affinity capture for selection and amplification of desired binding specificities.
- Reviewing existing research on phage-derived recombinant antibodies for tumor targeting.
Main Results:
- Phage display is an efficient strategy for isolating specific peptides and proteins.
- Phage-derived recombinant antibodies have demonstrated selective targeting of tumor-associated markers.
- Successful applications have been observed in both preclinical animal models and clinical studies.
Conclusions:
- Phage display technology is a powerful tool for developing targeted cancer therapeutics.
- Recombinant antibodies derived from phage display show promise for selective tumor targeting.
- Further research into other polypeptide classes could enhance targeted therapeutic agent delivery.